Search
Baloxavir marboxil
go.drugbank.com/drugs/DB13997ApprovedInvestigational[L4779] It was also approved by the European Commission on January 7, 2021.[L45241] … [A251760] Baloxavir marboxil was first globally approved in Japan in February 2018,[A39895] followed by the US approval in October, 2018.
Zolmitriptan
go.drugbank.com/drugs/DB00315ApprovedInvestigational[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. … [A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997.
Ceftobiprole
go.drugbank.com/drugs/DB04918ApprovedWithdrawnProducts for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European Union primarily due to data quality
Kappadione
go.drugbank.com/drugs/DB09332ApprovedKappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is
Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.
Ipecac
go.drugbank.com/drugs/DB13293ApprovedWithdrawn[L2753] Ipecac was approved by Health Canada as an OTC but all those products are now discontinued.
Pidolic acid
go.drugbank.com/drugs/DB03088ApprovedInvestigationalPidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics
Remestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawn[L11022] Remestemcel-L was later approved by the FDA on December 18, 2024. … of the recipients [A31818]. aGvHD is often characterized by the presence of inflammatory cascades through signalling of activated T cells.
Vismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigational[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. … In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Fecal microbiota
go.drugbank.com/drugs/DB17743ApprovedInvestigationalRecurrent CDI has a high risk of mortality and a high failure rate. … [A259172] REBYOTA, a live fecal microbiota suspension for rectal use, was approved by the FDA in November 2022.